Cargando…

Roles of NAD(+) in Acute and Chronic Kidney Diseases

Nicotinamide adenine dinucleotide (oxidized form, NAD(+)) is a critical coenzyme, with functions ranging from redox reactions and energy metabolism in mitochondrial respiration and oxidative phosphorylation to being a central player in multiple cellular signaling pathways, organ resilience, health,...

Descripción completa

Detalles Bibliográficos
Autores principales: Morevati, Marya, Fang, Evandro Fei, Mace, Maria L., Kanbay, Mehmet, Gravesen, Eva, Nordholm, Anders, Egstrand, Søren, Hornum, Mads
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820289/
https://www.ncbi.nlm.nih.gov/pubmed/36613582
http://dx.doi.org/10.3390/ijms24010137
_version_ 1784865430998876160
author Morevati, Marya
Fang, Evandro Fei
Mace, Maria L.
Kanbay, Mehmet
Gravesen, Eva
Nordholm, Anders
Egstrand, Søren
Hornum, Mads
author_facet Morevati, Marya
Fang, Evandro Fei
Mace, Maria L.
Kanbay, Mehmet
Gravesen, Eva
Nordholm, Anders
Egstrand, Søren
Hornum, Mads
author_sort Morevati, Marya
collection PubMed
description Nicotinamide adenine dinucleotide (oxidized form, NAD(+)) is a critical coenzyme, with functions ranging from redox reactions and energy metabolism in mitochondrial respiration and oxidative phosphorylation to being a central player in multiple cellular signaling pathways, organ resilience, health, and longevity. Many of its cellular functions are executed via serving as a co-substrate for sirtuins (SIRTs), poly (ADP-ribose) polymerases (PARPs), and CD38. Kidney damage and diseases are common in the general population, especially in elderly persons and diabetic patients. While NAD(+) is reduced in acute kidney injury (AKI) and chronic kidney disease (CKD), mounting evidence indicates that NAD(+) augmentation is beneficial to AKI, although conflicting results exist for cases of CKD. Here, we review recent progress in the field of NAD(+), mainly focusing on compromised NAD(+) levels in AKI and its effect on essential cellular pathways, such as mitochondrial dysfunction, compromised autophagy, and low expression of the aging biomarker αKlotho (Klotho) in the kidney. We also review the compromised NAD(+) levels in renal fibrosis and senescence cells in the case of CKD. As there is an urgent need for more effective treatments for patients with injured kidneys, further studies on NAD(+) in relation to AKI/CKD may shed light on novel therapeutics.
format Online
Article
Text
id pubmed-9820289
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98202892023-01-07 Roles of NAD(+) in Acute and Chronic Kidney Diseases Morevati, Marya Fang, Evandro Fei Mace, Maria L. Kanbay, Mehmet Gravesen, Eva Nordholm, Anders Egstrand, Søren Hornum, Mads Int J Mol Sci Review Nicotinamide adenine dinucleotide (oxidized form, NAD(+)) is a critical coenzyme, with functions ranging from redox reactions and energy metabolism in mitochondrial respiration and oxidative phosphorylation to being a central player in multiple cellular signaling pathways, organ resilience, health, and longevity. Many of its cellular functions are executed via serving as a co-substrate for sirtuins (SIRTs), poly (ADP-ribose) polymerases (PARPs), and CD38. Kidney damage and diseases are common in the general population, especially in elderly persons and diabetic patients. While NAD(+) is reduced in acute kidney injury (AKI) and chronic kidney disease (CKD), mounting evidence indicates that NAD(+) augmentation is beneficial to AKI, although conflicting results exist for cases of CKD. Here, we review recent progress in the field of NAD(+), mainly focusing on compromised NAD(+) levels in AKI and its effect on essential cellular pathways, such as mitochondrial dysfunction, compromised autophagy, and low expression of the aging biomarker αKlotho (Klotho) in the kidney. We also review the compromised NAD(+) levels in renal fibrosis and senescence cells in the case of CKD. As there is an urgent need for more effective treatments for patients with injured kidneys, further studies on NAD(+) in relation to AKI/CKD may shed light on novel therapeutics. MDPI 2022-12-21 /pmc/articles/PMC9820289/ /pubmed/36613582 http://dx.doi.org/10.3390/ijms24010137 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Morevati, Marya
Fang, Evandro Fei
Mace, Maria L.
Kanbay, Mehmet
Gravesen, Eva
Nordholm, Anders
Egstrand, Søren
Hornum, Mads
Roles of NAD(+) in Acute and Chronic Kidney Diseases
title Roles of NAD(+) in Acute and Chronic Kidney Diseases
title_full Roles of NAD(+) in Acute and Chronic Kidney Diseases
title_fullStr Roles of NAD(+) in Acute and Chronic Kidney Diseases
title_full_unstemmed Roles of NAD(+) in Acute and Chronic Kidney Diseases
title_short Roles of NAD(+) in Acute and Chronic Kidney Diseases
title_sort roles of nad(+) in acute and chronic kidney diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820289/
https://www.ncbi.nlm.nih.gov/pubmed/36613582
http://dx.doi.org/10.3390/ijms24010137
work_keys_str_mv AT morevatimarya rolesofnadinacuteandchronickidneydiseases
AT fangevandrofei rolesofnadinacuteandchronickidneydiseases
AT macemarial rolesofnadinacuteandchronickidneydiseases
AT kanbaymehmet rolesofnadinacuteandchronickidneydiseases
AT graveseneva rolesofnadinacuteandchronickidneydiseases
AT nordholmanders rolesofnadinacuteandchronickidneydiseases
AT egstrandsøren rolesofnadinacuteandchronickidneydiseases
AT hornummads rolesofnadinacuteandchronickidneydiseases